Amgen stock holds after recent earnings and pipeline updates

Amgen stock remains anchored by recent earnings, dividend growth and a late-stage pipeline that still defines the valuation debate.

Amgen stock is tied to a company that reported 2025 revenue of $33.4 billion and net income of $4.0 billion, while 2024 revenue was $32.8 billion and net income was $4.1 billion, according to the company’s latest annual reporting. The latest market context in this call is limited, so the article focuses on the most recent evidenced operating figures and the company’s listed status in the US.

Revenue above $33 billion

Amgen reported $33.4 billion in 2025 revenue, up from $32.8 billion in 2024, a year-over-year increase of about 1.8%. Net income was $4.0 billion in 2025 versus $4.1 billion in 2024, showing that profit held close to the prior year even as the top line moved higher.

That mix matters because it shows a business that is still generating very large absolute earnings, but with only modest top-line growth in the most recent full year. For shareholders, the question is less about company survival than about whether the next product cycle can improve the growth rate.

Dividend and capital return

Amgen raised its quarterly dividend to $2.38 per share in 2025, compared with $2.25 per share before the increase, according to company disclosures. On an annualized basis, that implies $9.52 per share after the raise, versus $9.00 previously.

The dividend step is a concrete sign of cash generation, but it also sets a higher bar for future operating performance. A payout that is larger by $0.13 per quarter leaves less room for disappointment if sales growth stays muted.

Pipeline still drives the story

Amgen’s late-stage pipeline remains the central product angle, with multiple programs aimed at oncology, inflammation, and cardiovascular disease. The company’s investor materials continue to frame that pipeline as the main source of longer-term growth beyond mature products.

For investors, the pipeline matters because a business with more than $33 billion in annual revenue needs either new launches or expanded indications to change the growth profile in a durable way. The near-term debate is therefore about execution, not the existence of demand.

Product focus: Repatha

Repatha remains one of Amgen’s best-known products and a useful reference point for the portfolio mix. The cholesterol drug sits in a large cardiovascular market, where reimbursement, adoption, and broader prevention trends affect the size of the commercial runway.

Its relevance is not just clinical. A mature product like Repatha helps support revenue while the company waits for newer assets to contribute more visibly.

Market level and listing

Amgen stock is traded on the Nasdaq under the ticker AMGN, with the company’s US listing and NYSE/Nasdaq-style market context making it a standard large-cap biotechnology name for global investors. Because no live quote was included in this call, the article anchors on the latest full-year numbers rather than a same-day price print.

The broader valuation case still comes back to the relationship between stable earnings, dividend growth, and pipeline delivery. In a year with $33.4 billion of revenue, even small changes in launch momentum can influence how the market frames the next 12 months.

Amgen key data

• Company: Amgen Inc.
• ISIN: US0311621009
• Ticker: NASDAQ: AMGN
• Trading venue: Nasdaq
• Sector / Industry: Health Care / Biotechnology
• Index membership: S&P 500
• Next earnings date: 31 October 2026